Janux Therapeutics Inc (JANX)
62.19
-2.59
(-4.00%)
USD |
NASDAQ |
May 06, 16:00
62.80
+0.61
(+0.98%)
After-Hours: 07:36
Janux Therapeutics Cash from Financing (TTM): 59.55M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 59.55M |
| September 30, 2023 | 58.91M |
| June 30, 2023 | 2.299M |
| March 31, 2023 | 2.079M |
| December 31, 2022 | 0.50M |
| September 30, 2022 | 0.473M |
| June 30, 2022 | -0.37M |
| Date | Value |
|---|---|
| March 31, 2022 | 328.98M |
| December 31, 2021 | 386.52M |
| September 30, 2021 | 390.91M |
| June 30, 2021 | 391.72M |
| March 31, 2021 | 67.57M |
| December 31, 2020 | 11.52M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.37M
Minimum
Jun 2022
391.72M
Maximum
Jun 2021
130.82M
Average
58.91M
Median
Sep 2023
Cash from Financing (TTM) Benchmarks
| Viking Therapeutics Inc | 873.23M |
| Equillium Inc | -9.228M |
| Minerva Neurosciences Inc | 19.60M |
| Arvinas Inc | 374.70M |
| Calidi Biotherapeutics Inc | -- |